Hanmi CEO On Success And Failure Of License Deals

No Need To Lose Hope When Assets Return

The CEO of South Korea's Hanmi Pharm shares experiences around licensing deals and turning around returned assets, identifying "great opportunities" in the near term for the country's pharma and biotech sectors as global partners continue to hunt for novel products and technologies.

success and failure
About 50% Of Licensed Out Assets Tend To Return To Originators • Source: Alamy

South Korea's Hanmi Pharmaceutical Co., Ltd. has struck the highest number of global licensing-out deals among its domestic peers in the past several years. Ironically, it has also seen many of those assets returned as the original arrangements fell apart for various reasons.

However, the company assured that there is no need to be too disappointed as there are still plenty of new...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia